The Biden administration is facing a new call to use its government authority to license an Astellas and Pfizer prostate cancer drug for generic manufacturing.
In a Tuesday letter, nongovernmental organization Knowledge Ecology International, Universities Allied for Essential Medicines, and the Union for Affordable Cancer Treatment urged the Department of Health and Human Services to license patents on the drug Xtandi to outside manufacturers to produce lower-cost versions of the drug.
KEI argues that two sections of the law—35 U.S.C. § 202(c)(4) and 28 U.S.C. 1498—allow the administration to license Xtandi patents to companies without having to pay ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.